On November 16th, 2024, Hasten announced that the first subject was enrolled and dosed in the Phase III clinical trial of the new third-generation PCSK9 inhibitor, Lerodalcibep (hereinafter referred to as HST101), which is jointly developed by Hasten and LIB.

On 16th, October 2024, Hasten Biopharmaceutical Co., Ltd. (hereinafter as Hasten) announced that a new network META article of azilsartan medoxomil (AZL-M) titled "A systematic literature review and network meta-analysis of azilsartan medoxomil compared to other anti-hypertensives efficacy in lowering blood pressure amongst mild to moderate hypertensive patients" had been published in the internationally renowned journal Advances in Therapy.

   

On Feb. 27th, 2024, Hasten Biopharmaceutical Limited Co., Ltd. (hereinafter as Hasten Biopharma) announced that the clinical trial application (IND) for Lerodalcibep, a novel third-generation PCSK9 inhibitor, has been accepted by the Center for Drug Evaluation(CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with hypercholesterolemia and further reduction their low-density lipoprotein cholesterol (LDL-C) levels.

“Edarbi® NRDL Launch Conference” was held in Beijing, Shanghai and Guangzhou on March 25 of 2023. More than 280 top domestic experts in the field of cardiovascular disease and management team from Hasten Biopharma attended the event, focusing on the review of the history for hypertension prevention and treatment in China during the past 30 years and discussion on a new chapter of blood pressure lowering and standardization.